A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(25 sites)

United States

Phoenix Children's Hospital, Phoenix, Arizona

Arkansas Children's Hospital, Little Rock, Arkansas

University of California, Los Angeles, Los Angeles, California

Stanford University, Palo Alto, California

University of California, San Francisco, San Francisco, California

Children's Hospital Colorado, Aurora, Colorado

Children's Hospital of Atlanta, Atlanta, Georgia

Riley Children's Hospital, Indianapolis, Indiana

Johns Hopkins Medical Institute, Baltimore, Maryland

Boston Children's Hospital, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

Washington University School of Medicine, St Louis, Missouri

UNC Chapel Hill, Chapel Hill, North Carolina

Australia

Sydney Children's Hospital, Randwick, Randwick, New South Wales

Monash Health, Clayton, Victoria

Murdoch Children's Research Institute, Parkville, Victoria

Belgium

UC Louvain, Ottignies-Louvain-la-Neuve

Italy

Ospedale Pediatrico Bambino Gesù IRCCS, Roma

Spain

Hospital Sant Joan de Deu, Barcelona

Hospital Universitario La Paz, Madrid

United Kingdom

Great Ormond Street Hospital for Children, London